Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix, Sony DADC to Develop and Manufacture Consumables for SiMoA Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quanterix and Sony DADC Austria today announced an agreement to develop and manufacture "smart consumables" for Quanterix's technology platform for the life sciences and in vitro diagnostic markets.

The companies are partnering on production of the Quanterix Single Molecule Array, or SiMoA, Discs, which would be the first diagnostic consumables with assay technology based on optical disc formats by Sony DADC, the two firms said.

Quanterix aims to develop and manufacture an automated instrument for its SiMoA technology, which will use the "smart consumables" to support a menu of diagnostic tests. The life science instrument and consumables are anticipated to reach the market in 2013. The company expects to commercialize an IVD platform in 2014.

"Partnering with Sony DADC on the SiMoA Disc is a major milestone toward our objective of delivering high-quality and cost-effective solutions to the clinical diagnostics and life science markets," Martin Madaus, executive chairman of Quanterix, said in a statement.

Earlier this year, the Cambridge, Mass.-based firm signed an agreement with Novartis for evaluation of the SiMoA platform for diagnostic purposes.